Cantor Fitzgerald maintains Vera Therapeutics at Overweight

Cantor Fitzgerald reaffirmed its Overweight rating on Vera Therapeutics (VERA) with a $100 price target, citing the upcoming Phase 3 ORIGIN trial data release for atacicept in late Q2 2025 as a potential catalyst. While VERA reported a larger-than-expected Q1 loss of $0.81 per share, the company's $589.8 million cash position is projected to fund operations through potential atacicept approval and commercial launch, with the firm also expanding atacicept's development program to include multiple autoimmune kidney diseases. The stock, currently trading near its 52-week low, is considered undervalued by some analysts despite a 59% decline over the past six months.

Analysis

Vera Therapeutics (VERA) has received a reaffirmed Overweight rating and a $100.00 price target from Cantor Fitzgerald, despite its stock trading at $19.64, near its 52-week low of $18.53. This endorsement highlights the potential of its lead drug candidate, atacicept, for which crucial Phase 3 ORIGIN trial data in IgA nephropathy (IgAN) is expected in late Q2 2025. Atacicept, which targets APRIL and BAFF and has received Breakthrough Designation, is central to the company's $1.25 billion market capitalization. Although Vera Therapeutics reported a wider-than-anticipated first-quarter net loss of $0.81 per share, totaling $51.7 million, compared to an estimated $0.73 loss, the company maintains a strong balance sheet with more cash than debt, reporting $589.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This financial position is projected by management to support operations through potential U.S. approval and commercial launch, with a Biologics License Application submission planned for Q4 2025. Despite a 59% stock decline over the past six months, InvestingPro analysis suggests the company is undervalued, and analyst price targets range broadly from $26 to $100. The upcoming trial data represents a significant inflection point, and the company is also expanding atacicept's development into multiple autoimmune kidney diseases.

Key Decisions for Investors

• Investors should weigh the high-risk, catalyst-driven nature of Vera Therapeutics, with the late Q2 2025 Phase 3 atacicept data release being a pivotal event that could significantly impact valuation.
• Consider the current stock price near its 52-week low and the 59% decline over six months against the reaffirmed $100 price target from Cantor Fitzgerald and the company's strong cash position, which may present a speculative opportunity for those with a high risk tolerance and a positive outlook on the trial.
• Monitor the company's progress towards its Q4 2025 Biologics License Application submission for atacicept and developments in its expanded program for other autoimmune kidney diseases, as these will be key indicators of long-term value beyond the initial IgAN indication.